Skip to search boxSkip to navigationSkip to main content

The antipsoriatic agent monomethylfumarate has antiproliferative, prodifferentiative, and anti-inflammatory effects on keratinocytes

  • Inas Helwa
    ,
  • Ravi Patel
    ,
  • Peter Karempelis
    ,
  • Ismail Kaddour-Djebbar
    ,
  • Vivek Choudhary
    ,
  • Wendy B. Bollag(corresponding author)
*Corresponding author for this work
  • Augusta University
    ,
  • VA Medical Center
    ,
  • Medical College of Georgia
    ,
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Monomethylfumarate (MMF) is thought to be the bioactive ingredient of the drug Fumaderm (Biogen Idec, Cambridge, MA), licensed in Germany since 1994 for the treatment of moderate-tosevere psoriasis. Psoriasis is a common inflammatory hyperproliferative skin disorder that involves cross-talk between different cell types, including immune cells and keratinocytes. Psoriatic lesions are characterized by hyperproliferation, aberrant differentiation, and inflammation, with the psoriatic cytokine network maintained by communication between immune cells and keratinocytes. Recently, there is increasing evidence regarding the pivotal role of keratinocytes in mediating the disease process, and these cells can be regarded as safe therapeutic targets. From the data available on human subjects treated with Fumaderm, MMF is an effective antipsoriatic agent with known effects on immune cells. However, little is known about its direct effects on keratinocytes. We hypothesized that MMF has direct antiproliferative, prodifferentiative, and anti-inflammatory effects on keratinocytes. Indeed, MMF dose-dependently inhibited [3H]thymidine incorporation into DNA, indicating a direct antiproliferative action on keratinocytes. MMF significantly increased the protein level of keratin 10, the early keratinocyte differentiation marker, and the activity of transglutaminase, a late differentiation marker. These results are consistent with an ability of MMF to promote keratinocyte differentiation and inhibit proliferation, thereby improving psoriatic lesions. In 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced keratinocytes, MMF significantly inhibited the expression of the proinflammatory cytokines, tumor necrosis factor-α (TNFα), interleukin-6, and interleukin-1a as well as the production of TNFα. Our results support the notion that MMF has direct antiproliferative, prodifferentiative, and anti-inflammatory effects on keratinocytes, highlighting its potential use as a multifactorial antipsoriatic agent.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Article number

A20

Pages from-to (Number of pages)

Pages 90-97 (8 pages)

Journal (Volume, Issue Number)

Journal of Pharmacology and Experimental Therapeutics (Volume 352, Issue 1)

Publication milestones

  • Published - 01/01/2015

Publication status

Published - 01/01/2015

ISSN

0022-3565

Publication IDs

  • Scopus: 84919775660
  • PubMed: 25332455
  • ORCID: /0000-0003-3146-162X/work/102843860

Publication metrics

Metrics

SciVal
FWCI
1.55
SciVal
Author count
6
SciVal
citations
17
SciVal
Paper percentile
79
Scopus
citations
Fractional count
2
Fractional count
0.33
Fractional count
4
Fractional count
0.67
Fractional count
2
Fractional count
1

PlumX, opens in new tab

Citation count
25
Captures
22

Funding Details

FundersFunding numbers
National Institute of Arthritis and Musculoskeletal and Skin Diseases
R01-AR45212
National Institutes of Health
-
U.S. Department of Veterans Affairs
CX000590
VA
I01CX000590